ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

Zwelling Moves to Legacy Community Health

July 19, 2013

Low Prevalence Of Tamoxifen Use For Cancer Prevention

February 26, 2010

Letter: Biostatistics Directors Invited To Share Concerns

June 7, 1996

In Brief: Michael Boyd Named New DTP Director; Saunders Retires; Michael Friedman New Chief Of CIB

October 7, 1983

Cancer Groups Fear Clinical Trials Coverage Will Not Be Implemented Across Exchanges

July 3, 2013

NCI Extramural Programs: NCAB Approves Guidelines for Cancer Center Grants

March 7, 1997